Physician profile
Luis DO Martinez
NPI 1366671042
$8,472.84
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $1,927 · 2021: $1,549 · 2022: $1,670 · 2023: $1,011 · 2024: $78.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,379.26 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $894.68 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.46 | 2019-2023 | Jardiance, Synjardy, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $737.27 | 2019-2023 | Breztri, Farxiga |
| Pfizer INC. | $655.32 | 2019-2024 | |
| Lilly USA, LLC | $448.56 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $422.22 | 2019-2023 | Verquvo, Lagevrio, Steglatro |
| Sanofi-Aventis U.S. LLC | $380.46 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $334.50 | 2019-2022 | |
| Amgen INC. | $284.07 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $263.60 | 2021-2023 | |
| Amarin Pharma, INC. | $209.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $202.25 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $185.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $172.39 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.